Evidence map›Paper›PMID 39755856›Full record

ArticleJournal of molecular medicine (Berlin, Germany)2025

CircRNA CDR1AS promotes cardiac ischemia-reperfusion injury in mice by triggering cardiomyocyte autosis.

Lina Xuan, Jun Chen, Hua Yang, Junwei Hao, Siyun Li, Qingqing Zhang, Hailong Zhang, Shengjie Wang, Huishan Luo, Jianjun Guo and 6 more

Abstract read
PubMed Publisher
In one paragraph

Article in Journal of molecular medicine (Berlin, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Lina Xuan *State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmacology, Joint International Research Laboratory of Cardiovascular Medicine Research, Ministry of Education, China, College of Pharmacy, Harbin Medical University, Harbin, 150081, Heilongjiang, China. hsuanswan@163.com.
Jun Chen *State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmacology, Joint International Research Laboratory of Cardiovascular Medicine Research, Ministry of Education, China, College of Pharmacy, Harbin Medical University, Harbin, 150081, Heilongjiang, China.
Hua Yang *State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmacology, Joint International Research Laboratory of Cardiovascular Medicine Research, Ministry of Education, China, College of Pharmacy, Harbin Medical University, Harbin, 150081, Heilongjiang, China.
Junwei Hao *State Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmacology, Joint International Research Laboratory of Cardiovascular Medicine Research, Ministry of Education, China, College of Pharmacy, Harbin Medical University, Harbin, 150081, Heilongjiang, China.
Siyun LiState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmacology, Joint International Research Laboratory of Cardiovascular Medicine Research, Ministry of Education, China, College of Pharmacy, Harbin Medical University, Harbin, 150081, Heilongjiang, China.
Qingqing ZhangState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmacology, Joint International Research Laboratory of Cardiovascular Medicine Research, Ministry of Education, China, College of Pharmacy, Harbin Medical University, Harbin, 150081, Heilongjiang, China.
Hailong ZhangState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmacology, Joint International Research Laboratory of Cardiovascular Medicine Research, Ministry of Education, China, College of Pharmacy, Harbin Medical University, Harbin, 150081, Heilongjiang, China.
Shengjie WangState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmacology, Joint International Research Laboratory of Cardiovascular Medicine Research, Ministry of Education, China, College of Pharmacy, Harbin Medical University, Harbin, 150081, Heilongjiang, China.
Huishan LuoState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmacology, Joint International Research Laboratory of Cardiovascular Medicine Research, Ministry of Education, China, College of Pharmacy, Harbin Medical University, Harbin, 150081, Heilongjiang, China.
Jianjun GuoState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmacology, Joint International Research Laboratory of Cardiovascular Medicine Research, Ministry of Education, China, College of Pharmacy, Harbin Medical University, Harbin, 150081, Heilongjiang, China.
Xingmei YangState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmacology, Joint International Research Laboratory of Cardiovascular Medicine Research, Ministry of Education, China, College of Pharmacy, Harbin Medical University, Harbin, 150081, Heilongjiang, China.
Guangze WangState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmacology, Joint International Research Laboratory of Cardiovascular Medicine Research, Ministry of Education, China, College of Pharmacy, Harbin Medical University, Harbin, 150081, Heilongjiang, China.
Feihan SunState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmacology, Joint International Research Laboratory of Cardiovascular Medicine Research, Ministry of Education, China, College of Pharmacy, Harbin Medical University, Harbin, 150081, Heilongjiang, China.
Xiaolin HuState Key Laboratory of Frigid Zone Cardiovascular Diseases (SKLFZCD), Department of Pharmacology, Joint International Research Laboratory of Cardiovascular Medicine Research, Ministry of Education, China, College of Pharmacy, Harbin Medical University, Harbin, 150081, Heilongjiang, China.
Kai KangDepartment of Cardiovascular Surgery, The First Affiliated Hospital of Harbin Medical University, Harbin, 150000, China. kangkai1975@sina.com.
Lihua SunCardiovascular Surgery Department of The First Affiliated Hospital of Harbin Medical University, and Pharmacology Department of Pharmacy College of Harbin Medical University, Harbin, 150081, China. sunlihua0219@163.com.ORCID http://orcid.org/0000-0002-0888-7991

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Myocardial ischemia/reperfusion (IR) injury is a common adverse event in the clinical treatment of myocardial ischemic disease. Autosis is a form of cell death that occurs when autophagy is excessive in cells, and it has been associated with cardiac IR damage. This study aimed to investigate the regulatory mechanism of circRNA CDR1AS on autosis in cardiomyocytes under IR. The expression of CDR1AS increases after myocardial IR, and overexpression of CDR1AS detrimentally affects cardiac function, increases infarct area, promotes excessive autophagy, and blocks the flow of autophagy to induce autosis after IR. Conversely, knockdown of CDR1AS reversed the autophagy-related markers caused by IR, increasing cardiomyocyte activity, improving cardiac dysfunction and infarct area, and restoring the flow of autophagy. Further analysis of RNA sequencing and validation experiments revealed that CDR1AS aggravated autophagic damage, increased autophagosome accumulation, and promoted autosis by inhibiting the levels of LAMP2 and mTORC1 proteins. Additionally, RIP and pull-down assays showed that CDR1AS interacts with LAMP2 or mTORC1. First-time evidence reveals that circRNA CDR1AS regulates lysosomal membrane proteins by regulating the mTORC1/ULK1 pathway during myocardial IR-induced autosis. This suggests that maintaining moderate autophagy is a crucial part of the fight against myocardial IR damage. KEY MESSAGES: CDR1AS expression was significantly increased in myocardium following IR. CDR1AS can increase the occurrence of autosis after IR. CDR1AS reduces the phosphorylation of ULK1, promoting the formation of autophagosomes. CDR1AS binds to LAMP2 and blocks the autophagosome clearance pathway. The specific mechanism of CDR1AS regulating IR is achieved by regulating autosis.

Indexed as

AutophagyMyocardial Reperfusion InjuryMyocytes, CardiacRNA, CircularAnimalsAutophagy-Related Protein-1 HomologDisease Models, AnimalLysosomal-Associated Membrane Protein 2MaleMechanistic Target of Rapamycin Complex 1MiceMice, Inbred C57BLSignal TransductionAutophagy-Related Protein-1 HomologLysosomal-Associated Membrane Protein 2Mechanistic Target of Rapamycin Complex 1RNA, CircularAutosisCDR1ASLAMP2MTORC1Myocardial ischemia/reperfusion injury

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.